India, May 26 -- Silexion Therapeutics Corp. (SLXN), a clinical-stage biotechnology company in RNA interference (RNAi) therapies for KRAS-driven cancers, announced a 1-for-10 reverse share split of its ordinary shares.
The adjustments will take effect after market close on May 28, 2026, with trading on a split-adjusted basis beginning at market open on May 29, 2026, under the existing ticker symbol "SLXN".
Following the split, every ten ordinary shares will be automatically combined into one share. A new CUSIP number will be assigned, and no fractional shares will be issued- eligible shareholders will receive rounded-up whole shares.
CEO Ilan Hadar described the move as "a deliberate step to preserve our Nasdaq listing and reinforce the ...